This work investigated how elimination of murine MHC together with different conditioning regimens shapes human T-cell maturation in vivo, and revealed marked differences in T-cell differentiation across models.
PD-L1/2-null TumorDressed DCs demonstrate robust priming of anti-tumor T cell-mediated cytotoxicity both in vitro and in vivo, including against primary hematologic and solid tumors with matching patient T cells.
Huaigeng Xu, Chisato Kamei, Deniz Gökbuget et al.· Cell Stem Cell· 0 citations
Invariant natural killer T (iNKT) cells can limit graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation (HSCT), but their scarcity in peripheral blood limits therapeutic development. Current clinical-grade human iNKT expansion protocols mainly rely on IL-2, require prior iNKT-cell sorting, last...
Jordan Brouard, Cristina Caraiman, Ghislain Fievet et al.· bioRxiv· 0 citations
Introduction Novel immunotherapeutic strategies engaging human Natural Killer (huNK) cells have emerged as a promising treatment paradigm; however, their accurate preclinical evaluation requires reliable mouse models capable of supporting functional huNK cell engraftment. Methods We developed and characterized robust i...
Pauline Rettman, Samira Benhamouche-Trouillet, Georges Azar et al.· Frontiers in Immunology· 0 citations
Immunodeficient and humanized mouse models have become essential tools for investigating human immunity, disease pathogenesis, and therapeutic evaluation. This review summarizes the stepwise evolution of these platforms, from nude and SCID mice to advanced NOD/SCID/Il2rgnull strains (NCG, NSG, or NOG), and highlights h...
Allogeneic CAR T cells could overcome limitations of autologous therapies but are limited by immune rejection. We evaluated 11 patients with large B‑cell lymphoma treated with a single lot of cemacabtagene ansegedleucel (cema-cel), an allogeneic anti‑CD19 CAR T product. Despite receiving identical infusion products, pa...
A. Jallouk, Zhong-Qi Ge, V. Kaimal et al.· Cancer Discovery· 0 citations
T cell receptor (TCR)-engineered T cells target antigens presented on major histocompatibility complex (MHC) class I molecules. MHC class I expression is often low in childhood tumors such as neuroblastoma but can be stimulated by interferon gamma (IFNγ). Chimeric antigen receptor (CAR) T cell effector function, in...
Alice Vitali, Jennie Padlo, Carlotta Caramel et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.